Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: An analysis from the early glycoprotein IIb/IIIa inhibition in patients with non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial

Circulation

Volumn 123, Issue 7, 2011, Pages 722-730

  Wang, Tracy Y ^a   White, Jennifer A ^a   Tricoci, Pierluigi ^a   Giugliano, Robert P ^b   Zeymer, Uwe ^c   Harrington, Robert A ^a   Montalescot, Gilles ^d   James, Stefan K ^e   Van De Werf, Frans ^f   Armstrong, Paul W ^g   Braunwald, Eugene ^b   Califf, Robert M ^h   Newby, L Kristin ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c KLINIKUM LUDWIGSHAFEN   (Germany)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF ALBERTA   (Canada)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute coronary syndrome; anticoagulants; clopidogrel; eptifibatide; platelets

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FONDAPARINUX; HEPARIN; HIRULOG; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIAC PATIENT; COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; THERAPY DELAY; THERAPY EFFECT;

ACUTE CORONARY SYNDROME; CORONARY ANGIOGRAPHY; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HEMORRHAGE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79952071585     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.958041     Document Type: Article

References (32)

1. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Chavey WE, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/NSTEMI: executive summary. Circulation. 2007;16:e148-e304.
2. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of NSTE ACS. Eur Heart J. 2007;28:1598-1660.
3. Soffer D, Moussa I, Harjai KJ, Boura JA, Dixon SR, Grines CL, O'Neill WW, Roubin GS, Moses JW. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv. 2003;59:21-25. (Pubitemid 36528793)
4. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with ACS without ST-segment elevation. N Engl J Med. 2001;345:494-502.
5. Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa receptor inhibition in NSTE ACS: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045-2048. (Pubitemid 29532053)
6. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention. Lancet. 2001;358:527-533. (Pubitemid 32772726)
7. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420. (Pubitemid 35340537)
8. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A. Abciximab in patients with ACS undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA. 2006;295:1531-1538.
9. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK. Early versus delayed, provisional eptifibatide in ACS. N Engl J Med. 2009;360:2176-2190.
10. Giugliano RP, Newby LK, Harrington RA, Gibson CM, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E. The EARLY ACS trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with NSTE ACS: study design and rationale. Am Heart J. 2005;149:994-1002.
11. Kolarov P, Tschöpe D, Nieuwenhuis HK, Gries FA, Strauer B, Schultheiss HP. PTCA: periprocedural platelet activation: Part II of the Duesseldorf PTCA Platelet Study. Eur Heart J. 1996;17:1216-1222. (Pubitemid 26289955)
12. Kereiakes DJ, Gurbel PA. Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. J Am Coll Cardiol Cardiovasc Interv. 2008;1:111-121. (Pubitemid 351506557)
13. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392-1397. (Pubitemid 39238016)
14. Mazzone A, De Servi S, Mazzucchelli I, Bossi I, Ottini E, Vezzoli M, Meloni F, Lotzinker M, Mariani G. Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. Heart. 2001;85:571-575. (Pubitemid 32973505)
15. Zia MI, Goodman SG, Peterson ED, Mulgund J, Chen AY, Langer A, Tan M, Ohman EM, Gibler WB, Pollack CV, Roe MT. Paradoxical use of invasive cardiac procedures for patients with NSTEMI: an international perspective from CRUSADE and the Canadian ACS Registries I and II. Can J Cardiol. 2007;23:1073-1079. (Pubitemid 351166035)
16. Fox KA. An international perspective on ACS care: insights from GRACE. Am Heart J. 2004;148(5 Suppl):S40-S45.
17. Wang TY, Chen AY, Alexander KP, Ohman EM, Gibler WB, Peterson ED, Roe MT. Excess heparin dosing among fibrinolytic-treated patients with STEMI. Am J Med. 2008;121:805-810.
18. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001;12:443-447. (Pubitemid 33097240)
19. Dalby M, Montalescot G, Bal dit Sollier C, Vicaut E, Soulat T, Collet JP, Choussat R, Gallois V, Drobinski G, Drouet L, Thomas D. Eptifibatide provides additional platelet inhibition in NSTEMI patients already treated with aspirin and clopidogrel. J Am Coll Cardiol. 2004;43:162-168.
20. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome. J Am Coll Cardiol. 1999;33:634-639.
21. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with NSTE ACS undergoing coronary stenting. J Am Coll Cardiol. 2006;48:1339-1345. (Pubitemid 44436814)
22. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. J Am Coll Cardiol. 2005;46:1827-1832. (Pubitemid 41579803)
23. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49:2312-2317. (Pubitemid 46891710)
24. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992-1000. (Pubitemid 351844676)
25. Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, Lincoff AM, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Circulation. 2001;103:2572-2578. (Pubitemid 32521967)
26. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with ACS undergoing percutaneous intervention. J Am Coll Cardiol. 2009;54:678-685.
27. PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
28. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with ACS. N Engl J Med. 1998;339:436-443.
29. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV, Peterson ED, Alexander KP. Baseline risk of major bleeding in NSTEMI: the CRUSADE bleeding score. Circulation. 2009;119:1873-1882.
30. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754-762.
31. Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC, Roe MT. Temporal trends in the use of early cardiac catheterization in patients with NSTE ACS. Am J Cardiol. 2006;98:1172-1176.
32. Montalescot G, Dabbous OH, Lim MJ, Flather MD, Mehta RH. Relation of timing of cardiac catheterization to outcomes in patients with NSTEMI or unstable angina pectoris enrolled in the multinational GRACE. Am J Cardiol. 2005;95:1397-1403.